首页 > 抗体蛋白 > 抗体
Brilliant Violet 605™ anti-mouse CD19 Antibo
产品名称:
Brilliant Violet 605™ anti-mouse CD19 Antibo
产品类别:
抗体
产品编号:
115539
产品应用:
115539
[价格]
规格 价格 库存
125µL ¥ 2508 1

产品详情

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CD19-expressing K562 human erythroleukemia cells
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA).
Preparation
The antibody was purified by affinity chromatography and conjugated with Brilliant Violet 605? under optimal conditions.
Concentration
?g sizes: 0.2 mg/mL
?L sizes: lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For immunofluorescent staining using the ?g size, the suggested use of this reagent is ≤0.5 ?g per million cells in 100 ?l volume. For immunofluorescent staining using the ?l size, the suggested use of this reagent is 5 ?l per million cells in 100 ?l staining volume or 5 ?l per 100 ?l of whole blood. It is recommended that the reagent be titrated for optimal performance for each application.

Brilliant Violet 605? excites at 405 nm and emits at 603 nm. The bandpass filter 610/20 nm is recommended for detection, although filter optimization may be required depending on other fluorophores used. Be sure to verify that your cytometer configuration and software setup are appropriate for detecting this channel. Refer to your instrument manual or manufacturer for support. Brilliant Violet 605? is a trademark of Sirigen Group Ltd.


Learn more about Brilliant Violet?.

This product is subject to proprietary rights of Sirigen Inc. and is made and sold under license from Sirigen Inc. The purchase of this product conveys to the buyer a non-transferable right to use the purchased product for research purposes only. This product may not be resold or incorporated in any manner into another product for resale. Any use for therapeutics or diagnostics is strictly prohibited. This product is covered by U.S. Patent(s), pending patent applications and foreign equivalents.
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunofluorescence7.

Application References

(PubMed link indicates BioLegend citation)
  1. Shoham T, et al. 2003. J. Immunol. 171:4062. (FC)
  2. Goodyear CS, et al. 2004. J. Immunol. 172:2870. (FC)
  3. Kamimura D, et al. 2006. J. Immunol. 177:306. (FC)
  4. Andoniou CE, et al. 2005. Nat. Immunol. 6:1011. (FC)
  5. Lawson BR, et al. 2007. J. Immunol. 178:5366. (FC)
  6. Phan TG, et al. 2007. Nat. Immunol. 8:992. (FC)
  7. Hayashida K, et al. 2008. J. Biol. Chem. 283:19895. (IF) PubMed
  8. Charles N, et al. 2010. Nat. Med. 16:701. (FC) PubMed
  9. Bankoti J, et al. 2010. Toxicol. Sci. 115:422. (FC) PubMed
  10. Stadnisky MD, et al. 2011. Blood. 117:5133. (FC) PubMed
  11. Perlot T, et al. 2012. J. Immunol. 188:1201. (FC) PubMed
  12. Olive V, et al. 2013. Elife. 2:822. PubMed
  13. Miyai T, et al. 2014. PNAS. 111:11780. PubMed
Product Citations
  1. Hutter K, et al. 2022. Front Immunol. 13:967914. PubMed
  2. Hu K, et al. 2022. J Extracell Vesicles. 11:e12199. PubMed
  3. Barrett N, et al. 2016. Cell Rep. 16: 1039-1054. PubMed
  4. Yu‐Han Chang et al. 2017. Immunity. 47(5):943-958 . PubMed
  5. Tran NT, et al. 2019. Cell Rep. 28:3510. PubMed
  6. Gawish R, et al. 2022. Elife. 11:. PubMed
  7. Rosenkranz SC, et al. 2021. eLife. 10:00. PubMed
  8. John S, et al. 2020. Sci Rep. 10:11377. PubMed
  9. Pokrovskii M, et al. 2019. Immunity. 51:185. PubMed
  10. Earnest JT, et al. 2021. Cell Reports. 35(1):108962. PubMed
  11. Benhamou D, et al. 2018. Front Immunol. 2.260416667. PubMed
  12. Starkl P, et al. 2020. Immunity. 53(4):793-804.e9. PubMed
  13. Maisonneuve C, et al. 2021. Cell Reports. 34(4):108677. PubMed
  14. Lee RD, et al. 2021. Nat Commun. 12:6843. PubMed
  15. van der Lelie D, et al. 2021. Nat Commun. 12:3105. PubMed
  16. Zhang R, et al. 2021. MAbs. 13:1904546. PubMed
  17. Ulrich-Lewis JT, et al. 2022. Front Immunol. 13:861710. PubMed
  18. Kim E, et al. 2022. STAR Protoc. 3:101366. PubMed
  19. Hutter K, et al. 2020. FEBS J. . PubMed
  20. Li J, et al. 2018. Immunity. 49:178. PubMed
  21. Ringel AE, et al. 2020. Cell. 183(7):1848-1866.e26. PubMed
  22. Schoeler K, et al. 2019. FEBS J. 10.1111/febs.14934. PubMed
  23. Alameh MG, et al. 2021. Immunity. 54:2877. PubMed
  24. White JM, et al. 2020. Mol Pharm. 2.165972222. PubMed
  25. Marcus A et al. 2018. Immunity. 49(4):754-763 . PubMed
  26. Van Winkle JA et al. 2018. Cell host & microbe. 24(5):665-676 . PubMed
  27. Jamali A, et al. 2020. Cell Reports. 32(9):108099. PubMed
  28. Sendler M, et al. 2020. Gastroenterology. 158:253. PubMed
  29. Kitajima Y, et al. 2022. Cells. 11:. PubMed
  30. Gomez S, et al. 2022. J Immunother Cancer. 10:. PubMed
  31. Colliou N, et al. 2015. Toxins. 7: 3805 - 3817. PubMed
  32. Melo-Silva CR, et al. 2021. PLOS Pathogens. 17(5):e1009593. PubMed
  33. Schuler F, et al. 2017. Nat Commun. . 10.1038/s41467-017-01850-4. PubMed
  34. Yousef H, et al. 2019. Nat Med. 25:988. PubMed
  35. Zheng Z, et al. 2021. Nat Commun. 12:6202. PubMed
  36. Casselli T, et al. 2021. PLoS Pathog. 17:e1009256. PubMed
  37. Fedele C, et al. 2021. J Exp Med. 218: . PubMed
  38. Subramaniam N, et al. 2021. Blood Adv. 5:1259. PubMed
  39. Heil J, et al. 2021. Nat Commun. 12:6963. PubMed
  40. Gong P, et al. 2022. Cell Death Discov. 8:466. PubMed
  41. Teng F, et al. 2021. Cell Rep. 37:110051. PubMed
  42. Tummala G, et al. 2021. Invest Ophthalmol Vis Sci. 62:41. PubMed
  43. Lederer K, et al. 2020. Immunity. 53(6):1281-1295.e5. PubMed
  44. Martins R, et al. 2016. Nat Immunol. 17:1361-1372. PubMed
  45. Parigger T, et al. 2021. Int J Mol Sci. 22:. PubMed
  46. Bramwell K, et al. 2015. J Immunol. 195: 1647 - 1656. PubMed
  47. Alterauge D, et al. 2020. Cell Rep. 33:108232. PubMed
  48. Miao Y et al. 2019. Cell. 177(5):1172-1186 . PubMed
  49. Lal JC, et al. 2021. Breast Cancer Res. 23:83. PubMed
  50. Nascimento DC, et al. 2021. Immunity. :. PubMed
  51. Laczkó D, et al. 2020. Immunity. 53:724. PubMed
RRID
AB_11203538 (BioLegend Cat. No. 115539) AB_2563067 (BioLegend Cat. No. 115540)

Antigen Details

Structure
Ig superfamily, associates with CD21 and CD81, 95 kD
Distribution

Pro-B cells to mature B cells (during development), follicular dendritic cells

Function
Modulates B cell activation and differentiation
Ligand/Receptor
CD21, CD81, Leu-13
Cell Type
B cells, Dendritic cells
Biology Area
Costimulatory Molecules, Immunology
Molecular Family
CD Molecules
Antigen References

1. Fearon DT. 1993. Curr. Opin. Immunol. 5:341.
2. Krop I, et al. 1996. Eur. J. Immunol. 26:238.
3. Krop I, et al. 1996. J. Immunol. 157:48.
4. Tedder TF, et al. 1994. Immunol. Today 15:437.

Gene ID
12478 View all products for this Gene ID
UniProt
View information about CD19 on UniProt.org

联系我们

TEL:021-34661275  点击拨打热线